nach oben

Current Hepatology Reports

Erschienen in:

23.10.2017 | Fatty Liver Disease (S Harrison and J George, Section Editors)

Overview of Clinical Treatment Trials for NASH

verfasst von: Monica A. Konerman, Stephen A. Harrison

Erschienen in: Current Hepatology Reports | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Non-alcoholic fatty liver disease (NAFLD) is one of the most prominent forms of chronic liver disease. Non-alcoholic steatohepatitis (NASH) represents a subgroup of patients with steatosis and necro-inflammation with or without fibrosis. Currently, there are no FDA-approved therapies. This review provides an overview of treatments in clinical trials for NAFLD and NASH.

Recent Findings

Therapies aimed at reducing hepatic steatosis focus on lipogenesis, insulin resistance, and metabolism of free fatty acids. Therapeutics targeting necro-inflammation have focused on pathways of immune activation and hepatocyte injury, while anti-fibrotic agents have focused on preventing fibrosis development via actions on stellate cells or reducing existing fibrosis.

Summary

There are multiple agents in mid-to-late stage clinical trials to treat NAFLD and NASH. Many have shown promising results. If safety and efficacy are established, these medications will provide a much needed pharmacologic treatment approach for this burgeoning patient population.

Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387–95.CrossRefPubMed

Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–85.CrossRefPubMed

Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol. 2008;103(9):2263–71.CrossRefPubMedPubMedCentral

•• Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017. https://doi.org/10.1002/hep.29367. Updated guidelines from AASLD on management of NAFLD/NASH.

Koehler E, Watt K, Charlton M. Fatty liver and liver transplantation. Clin Liver Dis. 2009;13(4):621–30.CrossRefPubMed

Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008;49(4):608–12.CrossRefPubMed

• Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–97.e10. Demonstrates impact of fibrosis stage on overall clinical outcomes.CrossRefPubMedPubMedCentral

• Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–54. Demonstrates impact of fibrosis stage on overall clinical outcomes.CrossRefPubMed

Sato K, Gosho M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, et al. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition. 2015;31(7–8):923–30.CrossRefPubMed

10.

Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297(8):842–57.CrossRefPubMed

11.

Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37–46.CrossRefPubMed

12.

Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549–56.CrossRefPubMedPubMedCentral

13.

Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, et al. Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. J Natl Cancer Inst. 2014;106(3):djt456.CrossRefPubMedPubMedCentral

14.

Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2012;35(1):66–75.CrossRefPubMed

15.

Mahady SE, Webster AC, Walker S, Sanyal A, George J. The role of thiazolidinediones in non-alcoholic steatohepatitis—a systematic review and meta analysis. J Hepatol. 2011;55(6):1383–90.CrossRefPubMed

16.

Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180–8.CrossRefPubMed

17.

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.CrossRefPubMed

18.

Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56(5):1751–9.CrossRefPubMed

19.

Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54(1):344–53.CrossRefPubMedPubMedCentral

20.

Fuchs M. Non-alcoholic Fatty liver disease: the bile acid-activated farnesoid x receptor as an emerging treatment target. J Lipids. 2012;2012:934396.CrossRefPubMed

21.

•• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–65. FLINT trial assessing OCA for treatment of NASH.CrossRefPubMed

22.

•• Ratziu V, Sanyal AJ, MacConell L, Shringarpure R, Marmon T, Shapiro D, et al. Regenerate: a phase 3, double-blind, randomized, placebo-controlled multicenter study of obeticholic acid therapy for nonalcoholic steatohepatitis. J Hepatol. 2016;64(2):S294–S5. Regenerate trial of OCA in NASH.CrossRef

23.

•• Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150(5):1147–59.e5. GOLDEN-505 trial evaluating impact of elafibranor in NASH.CrossRefPubMed

24.

Clinical Trials.gov. Randomized global phase 3 study to evaluate the impact on NASH with fibrosis of obeticholic acid treatment (REGENERATE). 2017.

25.

Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T, et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(12):2085–91.e1.CrossRefPubMed

26.

Clinical Trials.gov. A clinical trial to evaluate the efficacy and safety of two aramchol doses versus placebo in patients with NASH (Aramchol_005). 2017.

27.

Harrison SA Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, Bashir MB, Ling L, Rossi SJ, DePaoli AM, Rinella ME, Loomba R. NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients. EASL 2017.

28.

Sanyal A, Charles ED , Neuschwander-Tetri B, Loomba R, Harrison S, Abdelmalek MF, Lawitz E, Halegoua-Demarzio D, Dong Y, Noviello S, Krishnamoorthy S, Luo Y, Christian R. BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: a phase 2 study. EASL 2017.

29.

Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–90.CrossRefPubMed

30.

Loomba R, Lawitz E, Mantry PS, Jayakumar S, Caldwell SH, Arnold H, et al. GS-US-384-1497 Investigators. The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial. Hepatology. 2017. https://doi.org/10.1002/hep.29514

31.

Seki E, de Minicis S, Inokuchi S, Taura K, Miyai K, van Rooijen N, et al. CCR2 promotes hepatic fibrosis in mice. Hepatology. 2009;50(1):185–97.CrossRefPubMedPubMedCentral

32.

Lefebvre E, Moyle G, Reshef R, Richman LP, Thompson M, Hong F, et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One. 2016;11(6):e0158156.CrossRefPubMedPubMedCentral

33.

Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2017.

34.

Barreyro FJ, Holod S, Finocchietto PV, Camino AM, Aquino JB, Avagnina A, et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015;35(3):953–66.CrossRefPubMed

35.

Clinical Trials.gov. Emricasan, a Caspase Inhibitor, For evaluation in subjects with non-alcoholic steatohepatitis (NASH) fibrosis (ENCORE-NF). 2017.

36.

Garcia-Tsao F, McGuire Shiffman ML, Chan JL, Morris M, Yamashita M, Spada AP, Hagerty D. TITLE: Emricaaan (IDN-8556) administered orally for 28 days lowers portal pi'II88Ure in patients with compensated cirrhosis and severe portal hypertension AASLD Liver Meeting 2015.

37.

Clinical Trials.gov. Clinical trial to evaluate efficacy of GR-MD-02 for treatment of liver fibrosis in patients with NASH with advanced fibrosis (NASH-FX). 2017.

38.

Clinical Trials.gov. Clinical trial to evaluation the safety and efficacy of GR-MD-02 for the treatment of liver fibrosis and resultant portal hypertension in patients with Nash cirrhosis (NASH-CX). 2017.

Titel: Overview of Clinical Treatment Trials for NASH
verfasst von: Monica A. Konerman
Stephen A. Harrison
Publikationsdatum: 23.10.2017
Verlag: Springer US
Erschienen in: Current Hepatology Reports / Ausgabe 4/2017
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-017-0375-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Recent Advances in the Pathogenesis of Hepatitis C Virus-Related Non-Alcoholic Fatty Liver Disease and Its Impact on Patients Cured of Hepatitis C

Natural History of NAFLD/NASH

Managing the Burden of Non-NASH NAFLD

Managing HCC in NAFLD

Genetic and Epigenetic Associations of NAFLD: Focus on Clinical Decision Making